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Abstract 
Background: Ethanolic extract of Euryale ferox salisb. (EFx) may have an effect on the activity of hepatic antioxidant 
enzymes, glycemic control and lipid profile and histopathology of pancreas, liver and kidney of streptozotocin (STZ)—
induced diabetic wistar rats.
Methods: Wistar albino rats were divided into eight groups viz. non-diabetic (normal control), diabetic control (STZ-
induced), diabetic treated (infused with different doses of Euryale ferox. Salisb. ethanolic extract) and diabetic conven-
tional treated (treated with Glibenclamide). Diabetes was induced by administering streptozotocin (60 mg/kg body 
weight) intraperitoneal (i.p). The ethanolic extract was supplemented in different doses through oral route. Biochemi-
cal investigations were carried out according to previously reported methods. Histopathological examinations were 
done accordingly.
Results: The EFx supplemented diabetic rats significantly (p < 0.001) decreased the blood glucose level in a dose 
dependent manner. Plasma insulin level was significantly increased in EFx treated rats. The hepatic gluconeogenic 
enzymes activities were restored to normal in EFx treated rats. Activities of superoxide dismutase (SOD), catalase 
(CAT), glutathione peroxidase (GPx) and reduced glutathione (GSH) were significantly increased (p < 0.001) among 
EFx treated rats. Lipid profile was reinstated to nearly normal level among EFx treated rats. Histopathological investi-
gations revealed that microscopic architecture of pancreatic, hepatic and renal cells improvised in EFx treated diabetic 
rats.
Conclusion: EFx supplement could improve the glycemic control as well as lipid profile in diabetic rats along with 
improvised antioxidant enzymes which has beneficial effect in preventing the diabetic complications by scavenging 
the free radicals in diabetic rats.
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Background
There are several evidences that demonstrate that dia-
betic complications are closely associated with oxidative 
stress persuaded by free radicals generation (Pitkänen 
et al. 1992) Type-2 diabetes mellitus (T2DM) is a multi-
functional disease which is associated with hypergly-
cemia and lipoprotein abnormalities (Ugochukwu and 
Babady 2002). Damage to the cell, in turn results in the 
enhancement of reactive oxygen species (ROS) produc-
tion. Abnormally high level of ROS has been found to 
play an important role in causation of the development 
and pathogenesis of T2DM. Free radicals easily formed 
during diabetic state, serves an important role in the gen-
esis of diabetic complications (Ahmed et al. 2014a).
Antioxidant enzymes such as superoxide dismutase 
(SOD), catalase (CAT), glutathione peroxidase (GPx) and 
reduced glutathione (GSH) provides an important assis-
tance in scavenging the free radicals by breaking down 
the ROS. Prior researches have reported that a defect 
in the ROS scavenging machinery in T2DM patients as 
compared to the normal control (Ahmed et al. 2013).
Disturbances in the lipid profile is so high that diabe-
tes has been called “more a disease of lipid than carbo-
hydrate metabolism” (Rawi et  al. 1998). Levels of total 
cholesterol (TC), triglycerides (TG), low density lipopro-
tein cholesterol (LDL-c) were increased to a momentous 
level in T2DM. In contrast the level of high density lipo-
protein cholesterol (HDL-c) was significantly reduced in 
T2DM (Ahmed et al. 2014b; Kumar et al. 2013a, b).
Due to the competence of antioxidants to assuage oxi-
dative stress in cells and its contribution in helping to 
prevent diabetic complications, the chase for antioxi-
dants in the past decades has attracted much interest and 
many plants have been discovered to have great antioxi-
dant potential. Euryale ferox salisb. is an aquatic plant 
that belongs to family nymphaeaceae. It is also known 
as fox nut or gorgon nut. It is mainly distributed in East 
Asia to China to North and North East India. Eurylae 
ferox salisb. produces starchy white seeds which are edi-
ble. In India, the processed white seeds of Euryale ferox 
salisb. is known as Makhana. Leaves of E.Ferox salisb. 
are used in condition of difficult parturition (Duke and 
Ayensu 1985). Further, E.Ferox salisb. has also been used 
as traditional oriental medicine to treat various ailments 
including kidney failure, diarrhea and spleen dysfunc-
tion. Recent research studies indicate that E. Ferox salisb, 
seeds could reduce the myocardial ischemic reperfusion 
injury (Das et al. 2006). One of the recent study explores 
the antioxidant activities of the isolated compounds from 
E. Ferox Salisb. seeds (Song et al. 2011). The mechanism 
of action of STZ to induce diabetes is its selective toxicity 
to pancreatic β-cells via generation of NO free radicals. 
(Moncada et al. 1991). It is well known that the activity 
of free radical scavenging compounds i.e. antioxidant 
enzymes is very low in the islet of langerhans of pancreas 
as compared to the other tissues (Gandy et al. 1981). On 
the basis of antioxidant activity of the E. Ferox salisb. 
seeds, we aimed to investigate the plausible role of EFx 
on STZ-induced diabetic rats.
Thus, the present study was carried out to investigate 
the effect of ethanolic extract of E. Ferox salisb. on the 
carbohydrate metabolism, glycemic control, insulin level, 
hepatic gluconeogenic enzymes, renal function param-
eters and antioxidant enzymes level in conjunction with 




Healthy adult male albino Wistar rats, bred and reared 
at Indian Institute of Toxicological Research (IITR), 
Lucknow were used for purpose of the experimenta-
tion. Weight-matched animals (140–160 g) were selected 
and housed in polypropylene cages layered with husk 
and kept in a semi-natural light/dark condition (12  h 
light/12  h dark). The animals were allowed free access 
to water and standard pellet diet (Amrut Feeds, Pune, 
India).
Chemicals, reagents and biochemical estimation kits
Hexokinase, glucose-6-phosphate dehydrogenase, glu-
cose-6-phosphatase, fructose-1-6-bisphosphate were 
purchased from Sigma Aldrich (India). Blood glucose, 
lipid profile, and antioxidant enzymes kits were pur-
chased from Span Diagnostics, Surat (India). Streptozo-
tocin was purchased from Sigma Aldrich (India). Other 
needed chemicals used in the study were procured either 
from Sigma Aldrich (India) or CDH Mumbai (India).
Induction of diabetes
Wistar rats were injected intraperitoneally with STZ dis-
solved in 0.1  M citrate buffer (pH  =  6.5) at 60  mg/kg. 
Animals of control group received equal volume of vehi-
cle. After 48 h of STZ injection, blood glucose level of the 
diabetes induced rats was estimated. The rats depicting 
values ranging FBG ≥ 230 mg/dL, were considered to be 
diabetic.
Preparation of extracts
Extract of Euryale ferox salisb. seeds was prepared 
according to guideline of Lee et al. (Lee et al. 2002). Dried 
powder (100 g) of E. Ferox salisb. seeds was placed in a 
conical flask with 70% ethanol and extracted at 80°C for 
3  h. The filtration of the extract was performed along 
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with the concentration of the extract by rotary evaporator 
(Buchi, India) under low pressure. The resultant residue 
was freeze dried and stored at −70°C. After freeze dry-
ing the whole extract was eluted with n-hexane, dichlo-
romethane, ethyl acetate and n-butanol in a stepwise 
manner. After the sequential screening of the extract, the 
resultant fractions were collected and the remaining sol-
vents were removed by rotary evaporation. The powder 
(dried) was dissolved in dimethyl sulfoxide (DMSO) and 
diluted with phosphate buffered saline (pH  =  7.4). The 
percentage yield of the crude extract was calculated to be 
3.17%.
Administration of plant extracts
The extract of the parts of Euryale Ferox Salisb. (EFx) was 
administered to the rats through force-feeding gastric 
gavage route. This was executed by inserting an infant 
oral feeding tube, which was connected to a syringe con-
taining the extract, into the gastric region of the rat. The 
animals were fasted 30  min before and after the treat-
ment to ensure maximum bioavailability (Sridhar et  al. 
2005).
Preliminary study—determining the dosage for crude drug
One week after the induction of diabetes, rats with blood 
glucose level >250  mg/dL, were subjected to fasting for 
16  h. They were divided into different groups, with five 
rats in each group. N-hexane, di-chloromethane, ethyl 
acetate, n-butanol and aqueous extract ranging from 100 
to 800 mg/kg body weight, were administered to the ani-
mals and blood glucose was determined at the end of 5 h 
after the oral administration of the extracts (Karunanay-
ake et al. 1984). The lowest dose that brought about the 
maximum antihyperglycemic effect for each plant extract 
was given through oral intubations for the repeated 
administration. The effective dose of all the extracts was 
found to be 400 mg/kg body weight. The selected doses 
of the plant extracts were given on everyday till comple-
tion of the experiment (i.e., 45 days).
Repeated administration of E. Ferox salisb. seeds extract 
(EFx)
After a week of induction of diabetes in albino rats, fasting 
blood glucose levels of fasted rats was measured (Ahmed 
et  al. 2014a). Rats with plasma glucose level more than 
>250 mg/dL were included in the study. Rats were divided 
into seven groups of five each. Groups 1 and 2, viz, nor-
mal and diabetic control rats received vehicle alone [0.1% 
dimethyl sulfoxide (DMSO) 1 ml/kg body weight]. Groups 
3–6 were treated with the effective dose of n-hexane, 
di-chloromethane, ethyl acetate, n-butanol and water 
extracts dissolved in vehicle solution through oral route 
for 15 days, respectively. Group 7 was treated with insulin 
(3-IU/kg) for 15 days. Blood samples were collected peri-
odically. At the end of the repeated administration of the 
drug, the collected blood samples were analyzed for any 
toxic effect. Different doses of extract did not show any 
significant difference in the food consumption and body 
weight when compared to the normal rats. There was no 
lethality and toxicity found with any dose till the comple-
tion of the experiment. Therefore, the conclusion was that 
400 mg/kg body weight was safe to use.
Experimental design
A total of 35 male albino wistar rats were utilized and 
were randomly divided into 7 groups of 5 animals in each 
group:
Group I—Normal rats (untreated with dimethylsulfox-
ide, [DMSO].
Group-II—Diabetic control (administered with Strep-
tozotocin (STZ).
Group-III—Diabetic control + EFx seed extract (EFx) 
(100 mg/kg body weight).
Group-IV—Diabetic control + EFx seed extract (EFx) 
(200 mg/kg body weight).
Group-V—Diabetic control +  EFx seed extract (EFx) 
(300 mg/kg body weight).




The extract was administered to the respective groups 
through oral route using intragastric tube for 45 days.
Biochemical evaluation
Rats of the different groups were kept on fasting over-
night and the blood was withdrawn by retro orbital punc-
ture under light anesthesia. Blood was withdrawn from 
the rats on the 1st, 22nd and 45th day after the induction 
of diabetes to assess the blood glucose and plasma insulin 
level by glucose oxidase method (Kesari et al. 2005) and 
modified method of Herbert (Herbert et al. 1965) respec-
tively. The alteration in the body weight was observed 
throughout the therapy in the experimental animals.
Oral glucose tolerance test (OGTT) was performed 
according to the method described by Kumar et  al. 
(2013). OGTT was evaluated to determine the effect of 
EFx on peripheral utilization of glucose in normal rats. 
Wistar-albino rats were grouped into 7 groups (n =  5). 
All the rats were administered with different doses of 
EFx and Glibenclamide for 30  min. On completion of 
30 min all the groups received 2 g/kg of glucose by oral 
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route. The blood samples were collected at regular time 
period of 0, 0.5, 1.0, 1.5 and 2.0 h to estimate the oral glu-
cose tolerance. At the termination of treatment i.e. after 
45  days, animals were deprived of food for overnight. 
Activities of hepatic hexokinase, glucose-6-phsophatase, 
fructose-1-6-bisphosphatase, glucose-6-phosphate 
dehydrogenase were assayed according to the method 
of Branstrup (1957), method of Koide and Oda (1959), 
method of Gancedo (1971) and method of Robert (1966), 
respectively.
The level of the hexokinase was determined by the 
using reported method with minor modification (Bran-
strup et  al. 1957). The liver tissue was thawed, weighed 
and homogenized in ice-cold 0.1  M phosphate-buffered 
saline (pH 7.4) to a concentration of 50  mg/ml. The 
assay mixture contains the 7.5  mM MgCl2, 3.7  mM 
glucose, 11  mM thioglycerol and 45  mM HEPES 
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
buffer. Assay mixture 0.9  ml added into the culvert and 
0.3 ml of 0.22 M ATP added and mixed well. After that, 
0.1 ml of the tissue supernatant was added into the cul-
vert and determinations of the absorbance at 340 nm the 
hexokinase activity as units/min/mg of protein of tissue 
was recorded. The level of the glucose-6-phosphatase 
activity was measured according reported method of 
Koide et  al. with minor modification (Koide and Oda 
1959). Liver tissue was homogenate in ice-cold 0.1  M 
phosphate buffer saline (pH 7.4) to a concentration of 
50  mg/ml. 0.1  ml of 0.1  M glucose-6-phosphatase solu-
tion and 0.3 ml of 0.5 M maleic acid buffer (pH 6.5) was 
mixed in a test tube and incubated at 370°C for 15 min. 
The reaction was stopped by adding 1 ml of 10% trichlo-
roacetic acid, followed by chilling in ice, after stopping 
reaction the mixture was centrifuged at 3000  rpm for 
10  min. The absorbance was measured at the 340  nm 
and expressed of the glucose-6-phosphatase at the lib-
eration of the inorganic phosphate units/min/mg of 
protein of tissue. The level of the fructose-1,6-bispho-
sphatase was estimated by using the reported method 
with minor modification (Gancedo and Gancedo 1971). 
Liver tissue was homogenized in ice-cold 0.1  M phos-
phate buffer saline (pH 7.4). The assay mixture containing 
the 1.2 ml of trise HCl buffer (0.1 M, pH 7.0), 0.1 ml of 
substrate (0.05 M), 0.25 ml of MgCl2 (0.1 M), 0.1 ml of 
KCl (0.1  M), 0.25  ml of ethylenediaminetetraacetic acid 
(0.001  M) solution and 0.1  ml of enzyme homogenate 
and maintained the final sample volume 2 ml. The mix-
ture was incubated for 15 min at 370°C. The 10% solution 
of the trichloroethanoic acid was used for the termina-
tion of the reaction. The reaction mixture was centri-
fuged and the supernatant was used for the phosphorous 
estimation). In the supernatant, the 1 ml of ammonium 
molybdate and 0.4  ml of amino naphthol sulfonic acid 
were added. The blue color developed after 20  min and 
measurement of the absorbance at 680 nm was done. The 
activity of the fructose-1,6-bisphosphatase measured in 
units/min/mg of protein.
The lipid parameters viz. total cholesterol, HDL cho-
lesterol and triglycerides were evaluated according the 
methods of Zlatkis (1953), Burnstein (1970) and Foster 
and Dunn (1973), respectively. Level of serum LDL cho-
lesterol and VLDL cholesterol were estimated accord-
ing to the Friedewald formula (Friedewald et  al. 1972). 
Hepatic glycogen level was assessed by the method given 
by Kemp (1954). The levels of lipid peroxidation (LPO) 
in the tissues were evaluated by the method of Ohkawa 
(1979). Level of superoxide dismutase (SOD) was assayed 
by the method of Kakkar (1984). The level of catalase 
(CAT) enzyme was evaluated by the method given by 
Sinha (1972). Glutathione Peroxidase (GSH-Px) was 
assayed by the method given by Rotruck (1973). Level of 
reduced glutathione (GSH) was assessed by the method 
of Ellman (1959).
Production of liver and kidney homogenate
For the estimation of the antioxidant level, the rats of 
the respective groups were kept on fasting overnight. All 
the rats were decapitated and an abdominal incision was 
performed, in order to harvest liver and pancreas. The 
whole organs were thoroughly cleaned with chilled nor-
mal saline on ice. A 10% (w/v) homogenate of the liver 
and pancreas (0.03 M sodium phosphate buffer, pH-7.4) 
was prepared with the help of Ultra-Turrax homogenizer 
maintaining the speed at 9500 rpm.
Observation of general condition of rats
The overall general condition of rats such as psychologi-
cal activity, food intake, water intake, urine output, gen-
eral locomotion, and skin was observed every day. The 
parameters such as body weight and food intake were 
determined for every week.
Histological assessment of liver, kidney, pancreas 
and heart sample by Heamatoxylin Eosin (H/E) staining
At the end of the therapy, all the rats of different groups 
were sacrificed using mild anesthesia. After collection of 
the blood samples, the liver, kidney, pancreas and heart 
tissues were fixed in neutral formalin solution for 48  h, 
dehydrated by passing through graded series of alcohol 
embedded in paraffin blocks. 4  µm thick sections were 
prepared using a semi-automated rotator microtome.
Statistical analysis
Statistical analysis was performed using GRAPH PAD 
Prism software package, Version 5.0. All the data were 
expressed as mean  ±  standard error mean (SEM). The 
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comparisons within groups was evaluated utilizing inde-
pendent student T test and one way analysis of variance 
(ANOVA). The value of p < 0.05 or p < 0.01 was consid-
ered to be statistically significant.
Results
Effect of EFx on blood glucose level in normal and STZ 
induced diabetes treated rats
The biochemical parameters of glycemic control in the 
animals has been summarized in Table 1 (Figure 1). The 
intraperitoneal administration of streptozotocin (STZ) 
resulted in nearly fourfold increase of the fasting blood 
glucose levels in the male/female diabetic Wistar rats. 
The blood glucose level was measured at different time 
intervals during the research exertion viz. on the very 
first day of induction of diabetes, at the middle of the 
study i.e. on 21st day and at the end of the experiment 
i.e. on 45th day. It was observed that with the gradual 
increase in dose of the EFx, the blood glucose level was 
improvised. At the end of 45  days period, EFx treated 
diabetic animals showed a significant reduction of blood 
glucose level nearly to the normal level compared with 
the diabetic animals (p < 0.05).
Effect of EFx on plasma insulin level in normal and STZ 
induced diabetes treated rats
The level of plasma insulin was measured at differ-
ent periods during the experimentation. A significant 
decrease in the level of plasma insulin was observed in 
the untreated diabetic rats compared to the normal rats 
and the level of plasma insulin was further decreased in 
the untreated diabetic rats at the end of the study i.e. after 
45  days. Treatment with the methanol/dichlorometh-
ane extract of EFx in a dose dependent manner. Treat-
ment with 400 mg/kg body weight of EFx was shown to 
produce most significant (p < 0.05) effect on the level of 
plasma insulin. It amplified the level of plasma insulin 
nearly to the normal as compared to the other doses of 
EFx at the end of research exertion (Table 2; Figure 2).
Effect of EFx on OGTT in normal and STZ induced (treated) 
diabetic rats during 120 min (2 h)
The results from the research exertion clearly indicate 
that the of methanol/dichloromethane extract of Albizzia 
Lebbeck Benth. stem bark (EFx) (400 mg/kg body weight) 
and Glibenclamide (1 mg/kg) reduced the blood glucose 
level (significant hyperglycemia due to administration of 
glucose load of 2 g/kg p.o to a significant level (p < 0.05) 
after 2 h of oral administration as compared to the dia-
betic control group (Table 3; Figure 3).
Effect of EFx weight variation (grams) in normal and STZ 
induced diabetic (treated) rats
The body weight variation of the rats was observed at 
the beginning and end of the research exertion. As it is 
obvious from the table (Table 4; Figure 4), that weight of 
the diabetic (untreated) rats was reduced to a significant 
level. Weight of the EFx treated rats was increased to a 
momentous level (p < 0.05) as compared to the weight of 
normal rats.
Table 1 Effect of Euryale ferox salisb. seeds extract (EFx) on blood glucose level in normal and STZ induced diabetic 
treated rats
The data are expressed as mean ± SEM (n = number of animals in each group = 5). The comparisons has been made by one way ANOVA followed by Dunnent’s test.
ns non-significant, STZ Streptozotocin.
* p < 0.05 is considered as significant when compared to the control group (0 h).
** p < 0.001 is considered as very significant when compared to the control group (0 h).
*** p < 0.001 is considered as extremely significant when compared to the control group (0 h).
a Compared to diabetic control.
b Compared to normal control.
Groups Blood glucose level in mg/dL at different time intervals during  
experimentation
At start (on 1st day) On 21st day On 45th day
Normal rats [untreated with dimethylsulfoxide, (DMSO)] Group 1 82.38 ± 0.6308a 82.25 ± 0.2649a 81.80 ± 0.4055a
Diabetic control [administered with streptozotocin (STZ)] Group 2 303.8 ± 0.9011b 310.5 ± 0.2231b 312.5 ± 0.4212b
Diabetic + (EFx) (100 mg/kg body weight) Group 3 301.0 ± 0.2698 264.1 ± 1.152 201.7 ± 0.3738
Diabetic + (EFx) (200 mg/kg body weight) Group 4 297.8 ± 0.3096 235.4 ± 0.8799 173.1 ± 0.8970
Diabetic + (EFx) (300 mg/kg body weight) Group 5 295.4 ± 0.3857 184.0 ± 0.6072 107.6 ± 1.422**
Diabetic + (EFx) (400 mg/kg body weight) Group 6 293.6 ± 0.3771 146.7 ± 0.5004 91.08 ± 0.5402***
Diabetic + glibenclamide (1 mg/kg body weight) Group 7 290.9 ± 0.2182 117.4 ± 1.004** 83.14 ± 0.6532***
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Figure 1 Effect of EFx on blood glucose level at different time interval of therapy, Group 1: normal control; Group 2: STZ (60 mg/kg i.p.); Group 3: 
diabetic control + (EFx) (100 mg/kg body weight); Group 4: diabetic control + (EFx) (200 mg/kg body weight) and continue for 45 days; Group5: 
diabetic + diabetic control + (EFx) (300 mg/kg body weight) and continue for 45 days; Group 6: diabetic control + (EFx) (400 mg/kg body weight) 
and continue for 45 days; Group 7: diabetic control + glibenclamide (1 mg/kg body weight) and continue for 45 days.
Table 2 Effect of Euryale ferox salisb. seed extract (EFx) on plasma insulin level in normal and STZ induced and treated 
diabetic rats
The data are expressed as mean ± SEM (n = number of animals in each group = 5). The comparisons has been made by one way ANOVA followed by Dunnent’s test.
ns non-significant, STZ Streptozotocin.
* p < 0.05 is considered as significant when compared to the control group (0 h).
** p < 0.001 is considered as very significant when compared to the control group (0 h).
*** p < 0.001 is considered as extremely significant when compared to the control group (0 h).
a  Compared to diabetic control.
b Compared to normal control.
Groups Plasma insulin level in µM at different time interval  
of experimentation
At start (on 1st day) On 21st day On 45th day
Normal rats [untreated with dimethylsulfoxide, (DMSO)] Group 1 12.22 ± 0.2028a 12.37 ± 0.1772a 12.39 ± 0.1154a
Diabetic control [administered with Streptozotocin (STZ)] Group 2 3.710 ± 0.1482b 3.136 ± 0.01208b 3.034 ± 0.02482b
Diabetic + (EFx) (100 mg/kg body weight) Group 3 4.260 ± 0.1040 5.812 ± 0.03929 6.822 ± 0.02596
Diabetic + (EFx) (200 mg/kg body weight) Group 4 4.250 ± 0.02168 6.028 ± 0.005831 7.936 ± 0.02542
Diabetic + (EFx) (300 mg/kg body weight) Group 5 4.806 ± 0.03655 7.058 ± 0.03277 9.496 ± 0.1394**
Diabetic + (EFx) (400 mg/kg body weight) Group 6 4.896 ± 0.02786 9.136 ± 0.04854** 11.66 ± 0.1689***
Diabetic + glibenclamide (1 mg/kg body weight) Group 7 5.058 ± 0.03382 9.734 ± 0.09304** 12.34 ± 0.1080***
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Figure 2 Effect of EFx on plasma insulin level at different time interval of therapy, Group 1: normal control; Group 2: STZ (60 mg/kg i.p.); Group 3: 
diabetic control + (EFx) (100 mg/kg body weight); Group 4: diabetic control + (EFx) (200 mg/kg body weight) and continue for 45 days; Group5: 
diabetic + diabetic control + (EFx) (300 mg/kg body weight) and continue for 45 days; Group 6: diabetic control + (EFx) (400 mg/kg body weight) 
and continue for 45 days; Group 7: diabetic control + glibenclamide (1 mg/kg body weight) and continue for 45 days.
Table 3 Effect of Euryale ferox salisb. seeds extract (EFx) during 120 min (2 h) on OGTT in normal and STZ induced dia-
betic (treated) rats
The data are expressed as mean ± SEM (n = number of animals in each group = 5). The comparisons has been made by one way ANOVA followed by Dunnent’s test.
ns non-significant, STZ Streptozotocin.
* p < 0.05 is considered as significant when compared to the control group (0 h).
** p < 0.001 is considered as very significant when compared to the control group (0 h).
*** p < 0.001 is considered as extremely significant when compared to the control group (0 h).
a Compared to diabetic control.
b Compared to normal control.
Groups Time (h)
0 h 0.5 h 1 h 1.5 h 2 h
Normal rats [untreated with dimethylsulfoxide, (DMSO)] 
Group 1
82.91 ± 0.3829a 95.60 ± 0.2651a 108.62 ± 0.3387a 117.67 ± 0.9812a 138.15 ± 0.4991a
Diabetic control (administered with Streptozotocin (STZ) 
Group 2
265.9 ± 0.9826b 278.2 ± 0.8519b 284.7 ± 0.2911b 279.1 ± 0.8171b 274.9 ± 0.3012b
Diabetic + (EFx) (100 mg/kg body weight) Group 3 235.0 ± 1.086 225.0 ± 0.8882 221.0 ± 0.2465 203.9 ± 0.8683 182.4 ± 0.2997
Diabetic + (EFx) (200 mg/kg body weight) Group 4 225.2 ± 0.9767 214.8 ± 0.8538 212.4 ± 0.2989 198.0 ± 0.6565 171.6 ± 0.4256
Diabetic + (EFx) (300 mg/kg body weight) Group 5 214.2 ± 1.263 211.5 ± 0.6072 202.8 ± 0.4556 185.7 ± 1.784 142.8 ± 0.7964**
Diabetic + (EFx) (400 mg/kg body weight) Group 6 203.1 ± 1.652 192.3 ± 0.5702 182.8 ± 0.3597 162.4 ± 0.4513* 88.45 ± 0.7672***
Diabetic + glibenclamide (1 mg/kg body weight) Group 7 198.3 ± 0.5980 182.4 ± 0.5737 170.9 ± 0.3304 141.7 ± 0.5050** 82.80 ± 0.5378***
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Figure 3 Effect of EFx on oral glucose tolerance test (OGTT) during 120 min (2 h) of therapy, Group 1: normal control; Group 2: STZ (60 mg/kg i.p.); 
Group 3: diabetic control + (EFx) (100 mg/kg body weight); Group 4: diabetic control + (EFx) (200 mg/kg body weight) and continue for 45 days; 
Group 5: diabetic + diabetic control + (EFx) (300 mg/kg body weight) and continue for 45 days; Group 6: diabetic control + (EFx) (400 mg/kg body 
weight) and continue for 45 days; Group 7: diabetic control + glibenclamide (1 mg/kg body weight) and continue for 45 days.
Table 4 Effect of Euryale ferox salisb. seeds extract (EFx) on body weight variation (grams) in normal and STZ induced 
diabetic treated rats
The data are expressed as mean ± SEM (n = number of animals in each group = 5). The comparisons has been made by one way ANOVA followed by Dunnent’s test.
ns non-significant, STZ Streptozotocin.
* p < 0.05 is considered as significant when compared to the control group (0 h).
** p < 0.001 is considered as very significant when compared to the control group (0 h).
*** p < 0.001 is considered as extremely significant when compared to the control group (0 h).
a  Compared to diabetic control.
b Compared to normal control.
Groups Time (h)
1st day 45th day
Normal rats [untreated with dimethylsulfoxide, (DMSO)] Group 1 263.6 ± 0.8124a 265.0 ± 1.673a
Diabetic control [(administered with Streptozotocin (STZ)] Group 2 213.8 ± 1.594b 210.8 ± 0.4899b
Diabetic + (EFx) (100 mg/kg body weight) Group 3 217.0 ± 1.140 222.8 ± 1.655
Diabetic + (EFx) (200 mg/kg body weight) Group 4 220.6 ± 0.2449 234.2 ± 1.463
Diabetic + (EFx) (300 mg/kg body weight) Group 5 222.6 ± 0.5099 237.6 ± 0.5099
Diabetic + (EFx) (400 mg/kg body weight) Group 6 226.2 ± 0.8000 252.6 ± 1.631**
Diabetic + glibenclamide (1 mg/kg body weight) Group 7 227.0 ± 0.9487 262.0 ± 0.7071***
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Effect of EFx on hepatic enzymes in normal and STZ 
induced diabetic treated rats
Table  5 (Figure  5) portrays the alteration in the activi-
ties of carbohydrate metabolizing enzymes in the liver of 
diabetic control group and other groups of experimental 
animals. The activities of hepatic hexokinase and glu-
cose-6-phosphate dehydrogenase (G6PD) were found 
to be decreased. On the other hand, the level of glu-
coneogenic enzymes viz. glucose-6-phosphatase and 
fructose-6-phosphatase were significantly increased in 
Figure 4 Effect of EFx on body weight variation at different time interval of therapy, Group 1: normal control; Group 2: STZ (60 mg/kg i.p.); Group 
3: diabetic control + (EFx) (100 mg/kg body weight); Group 4: diabetic control + (EFx) (200 mg/kg body weight) and continue for 45 days; Group 5: 
diabetic + diabetic control + (EFx) (300 mg/kg body weight) and continue for 45 days; Group 6: diabetic control + (EFx) (400 mg/kg body weight) 
and continue for 45 days; Group 7: diabetic control + glibenclamide (1 mg/kg body weight) and continue for 45 days.
Table 5 Effect of Euryale ferox salisb. seeds extract (EFx) on hepatic enzymes in normal and STZ induced diabetic treated 
rats
The data are expressed as mean ± SEM. (n = number of animals in each group = 5). The comparisons has been made by one way ANOVA followed by Dunnent’s test
ns non-significant, STZ Streptozotocin.
* p < 0.05 is considered as significant when compared to the control group (0 h).
** p < 0.001 is considered as very significant when compared to the control group (0 h).
*** p < 0.001 is considered as extremely significant when compared to the control group (0 h).
a Compared to diabetic control.
b Compared to normal control.













Normal rats [untreated with 
dimethylsulfoxide, (DMSO)] 
Group 1
0.2360 ± 0.007483a 0.0356 ± 0.0002449a 0.0320 ± 0.0004472a 0.1620 ± 0.003742a
Diabetic control (administered with 
Streptozotocin (STZ) Group 2
0.0880 ± 0.003742b 0.0646 ± 0.002249b 0.0664 ± 0.0009274b 0.0714 ± 0.0006782b
Diabetic + (EFx) (100 mg/kg body 
weight) Group 3
0.1080 ± 0.003742 0.0602 ± 0.0004899 0.0584 ± 0.0007483 0.0754 ± 0.0012080
Diabetic + (EFx) (200 mg/kg body 
weight) Group 4
0.1400 ± 0.003162 0.0548 ± 0.0005831 0.0526 ± 0.0014 0.0822 ± 0.00080000
Diabetic + (EFx) (300 mg/kg body 
weight) Group 5
0.1800 ± 0.003162 0.0464 ± 0.0009274 0.0466 ± 0.001030 0.08808 ±  0.01949
Diabetic + (EFx) (400 mg/kg body 
weight) Group 6
0.2024 ± 0.0006782** 0.0408 ± 0.0003742** 0.0376 ± 0.0005099*** 0.1340 ± 0.0050990**
Diabetic + glibenclamide (1 mg/kg 
body weight) Group 7
0.2220 ± 0.003742*** 0.0532 ± 0.001497** 0.0454 ± 0.002315** 0.1144 ± 0.003919**
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the diabetic animals compared to those in normal rats. 
Administration of different doses of EFx among diabetic 
rats reversed the alterations in the hepatic enzymes such 
that animals received 400  mg/kg body weight showed 
the significant improvement (p < 0.05) in all the hepatic 
enzymes alterations as compared to the other doses.
Effect of EFx on serum lipid profile in normal and STZ 
induced among diabetic (treated) rats
As Evident from the Table 6 that diabetic rats exhibited 
significant increase in serum total cholesterol, VLDL 
cholesterol, LDL cholesterol, triglycerides levels and 
decreased level of HDL cholesterol and hepatic glycogen. 
Lipid profile of the EFx treated diabetic rats was signifi-
cantly improved (p < 0.05) as compared to the untreated 
diabetic rats (Figure 6).
Effect of EFx on oxidative stress parameters in normal 
and STZ induced diabetic (treated) rats
Table  7 clearly illustrates the effect of EFx on the anti-
oxidant enzymes. A marked reduction was noted in the 
level of superoxide dismutase (SOD), catalase (CAT), 
Glutathione Peroxidase (GSH-Px), and reduced glu-
tathione (GSH) in the STZ induced diabetic rats. Admin-
istration of EFx at different doses for the 45 days to STZ 
induced diabetic rats significantly (p  <  0.05) increased 
SOD, CAT, GSH-Px levels with maximum effect seen at 
400  mg/kg body weight. The enhanced level of TBARS 
was reversed to near normal after administration of EFx 
after administering 400 mg/kg body weight of EFx. It is 
pertinent to note that the EFx was found to be equipped 
with the antioxidant effect in a dose dependent manner 
(Figure 7).
Figure 5 Effect of EFx on various hepatic enzymes at the end of therapy, Group 1: normal control; Group 2: STZ (60 mg/kg i.p.); Group 3: diabetic 
control + (EFx) (100 mg/kg body weight); Group 4: diabetic control + (EFx) (200 mg/kg body weight) and continue for 45 days; Group 5: dia-
betic + diabetic control + (EFx) (300 mg/kg body weight) and continue for 45 days; Group 6: diabetic control + (EFx) (400 mg/kg body weight) and 
continue for 45 days; Group 7: diabetic control + glibenclamide (1 mg/kg body weight) and continue for 45 days.
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Effect of EFx on histopathology of pancreas, kidney, liver 
and heart
Pancreas
Normal control rats exhibited normal histological archi-
tecture. Many rounded normal proportions of islet of 
langerhans were found all around the pancreatic acini. 
Prominent nuclei with well arranged lobules with sur-
rounding islet cells, were found among normal control 
rats (Figure 8). Groups received STZ, demonstrated cel-
lular damage to the pancreatic acini and islets, which 
showed pancreatic β-cell damage and degeneration with 
asymmetrical vacuoles. EFx treated STZ induced-DM 
rats showed marked improvement of the cellular injure as 
(Figure 9), as evident from the partial restoration of islet 
cells, reduced β-cell damage, more symmetrical vacuoles 
and an increase in number of islet cells.
Kidney
Morphological features of kidney remained normal in 
the control group like prominent glomeruli, collect-
ing ducts, tubules and ascending and descending loops. 
STZ-induced DM group showed presence of crystal 
deposition on the glomeruli along with destructed glo-
meruli and infiltration of red blood cells (Figure  8). 
Groups received the EFx demonstrated reversal of these 
pathological destructions as apparent by the cells regen-
eration and removal of crystals deposition.
Liver
The liver cells of normal control groups showed eminent 
hepatocytes with central vein along with portal triad 
(Figure 10). The damage to the liver cells in the form of 
damaged central vein, hepatocytes and portal trial could 
be clearly seen in the group received STZ. The dam-
age to the liver cells were reversed in all the EFx treated 
groups.
Discussion
Acute toxicity study of the methanolic extract dem-
onstrated that different doses of Euryale ferox salisb. 
were non-toxic throughout the experiment. The lethal-
ity was found to be zero in the groups received the dif-
ferent doses of Euryale ferox salisb. seeds extract. Oral 
glucose tolerance test studies showed EFx significantly 
Table 6 Effect of Euryale ferox salisb. seeds extract (EFx) on lipid profile in normal and STZ induced and diabetic (treated) 
rats
The data are expressed as mean ± SEM (n = number of animals in each group = 5). The comparisons has been made by one way ANOVA followed by Dunnent’s test.
ns non-significant, STZ Streptozotocin.
* p < 0.05 is considered as significant when compared to the control group (0 h).
** p < 0.001 is considered as very significant when compared to the control group (0 h).
*** p < 0.001 is considered as extremely significant when compared to the control group (0 h).
a  Compared to diabetic control.
b Compared to normal control.









Hepatic glycogen (mg 
glucose equivalents/
mg wet tissue)
Normal rats [untreated with dimethyl-
sulfoxide, (DMSO)] Group 1
137.7 ± 1.315a 63.19 ± 0.4878a 23.54 ± 0.5120a 67.57 ± 0.5943a 55.70 ± 1.523a
Diabetic control [(administered with 
Streptozotocin (STZ)] Group 2
283.0 ± 0.7544b 16.65 ± 0.1162b 114.6 ± 0.5353b 203.7 ± 0.8567b 15.61 ± 0.1631b
Diabetic + (EFx) (100 mg/kg body 
weight) Group 3
231.8 ± 0.3189 24.83 ± 0.4556 92.14 ± 0.2920 184.7 ± 0.6979 20.97 ± 0.2149
Diabetic + (EFx) (200 mg/kg body 
weight) Group 4
198.1 ± 0.4720 36.27 ± 0.5386 71.43 ± 0.4485 141.6 ± 0.5797 34.01 ± 0.7427
Diabetic + (EFx) (300 mg/kg body 
weight) Group 5
172.8 ± 0.3100 42.49 ± 0.7798 53.04 ± 0.2755 111.3 ± 0.4677 42.61 ± 0.4618
Diabetic + (EFx) (400 mg/kg body 
weight) Group 6
151.4 ± 0.4808*** 58.34 ± 0.5236*** 32.03 ± 0.5791** 74.77 ± 1.225** 51.68 ± 0.3041***
Diabetic + glibenclamide (1 mg/kg 
body weight) Group 7
165.7 ± 0.5246** 41.62 ± 0.2302** 47.58 ± 0.4332** 91.99 ± 0.5388** 55.79 ± 0.9709**
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Figure 6 Effect of EFx on lipid profiles at the end of therapy, Group 1: normal control; Group 2: STZ (60 mg/kg i.p.); Group 3: diabetic control + (EFx) 
(100 mg/kg body weight); Group 4: diabetic control + (EFx) (200 mg/kg body weight) and continue for 45 days; Group 5: diabetic + diabetic 
control + (EFx) (300 mg/kg body weight) and continue for 45 days; Group 6: diabetic control + (EFx) (400 mg/kg body weight) and continue for 
45 days; Group 7: diabetic control + glibenclamide (1 mg/kg body weight) and continue for 45 days.
Table 7 Effect of Euryale ferox salisb. seeds extract (EFx) on oxidative stress parameters in liver of normal and STZ 
induced diabetic treated rats
The data are expressed as mean ± SEM (n = number of animals in each group = 5). The comparisons has been made by one way ANOVA followed by Dunnent’s test.
ns non-significant, STZ Streptozotocin.
* p < 0.05 is considered as significant when compared to the control group (0 h).
** p < 0.001 is considered as very significant when compared to the control group (0 h).
*** p < 0.001 is considered as extremely significant when compared to the control group (0 h).
a Compared to diabetic control.




CAT (µ mol/min/mg 
protein)




Normal rats [untreated with dimethylsulfoxide, 
(DMSO)] Group 1
12.30 ± 0.1642a 82.84 ± 0.6566a 13.71 ± 0.1077a 53.63 ± 0.1813a
Diabetic control [administered with Streptozotocin 
(STZ)] Group 2
3.670 ± 0.07218b 22.28 ± 0.2578b 5.274 ± 0.1402b 21.98 ± 0.2745b
Diabetic + (EFx) (100 mg/kg body weight) group 3 5.726 ± 0.1197 36.09 ± 0.2578 7.628 ± 0.08243 35.30 ± 0.3952
Diabetic + (EFx) (200 mg/kg body weight) Group 4 8.366 ± 0.01965 48.08 ± 0.4018 8.820 ± 0.01304 39.09 ± 0.2614
Diabetic + (EFx) (300 mg/kg body weight) Group 5 9.440 ± 0.1626 68.61 ± 0.2086 10.29 ± 0.2236 43.76 ± 0.4200
Diabetic + (EFx) (400 mg/kg body weight) Group 6 11.47 ± 0.1209*** 76.68 ± 0.8596** 12.64 ± 0.04104*** 50.91 ± 0.3273***
Diabetic + Glibenclamide (1 mg/kg body weight) 
Group 7
9.608 ± 0.1329** 71.70 ± 0.3430** 10.53 ± 0.1955** 34.52 ± 0.3057**
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(88.45 ± 0.7672) declined the level of the blood sugar 
when compared to the glibenclamide (82.80 ± 0.5378). 
Glibenclamide is often used as insulin stimulant in 
many studies and also as standard antidiabetic drug 
in STZ-induced moderate diabetes to compare the 
antidiabetic potential of various hypoglycemic agents 
(Andrade et al. 2000). Furthermore, the blood glucose 
level of STZ-induced diabetic rats was increased to a 
significant level. EFx treated STZ-induced diabetic 
rats, lowers the increased blood glucose level to a sig-
nificant (91.08 ± 0.5402) extent. EFx treated group rats 
showed improved level of the insulin as compared to 
the glibenclamide. It has been stated that most of the 
diabetic complications are mediated through oxida-
tive stress (Matkovics et al. 1997; Kavalali et al. 2003). 
Studies also suggest involvement of free radicals in 
pancreatic cell destruction (Lenzen 2008). Histopatho-
logical studies of the sections of pancreas, liver and 
kidney revealed the disturbed morphological features. 
Islets of langerhans containing β-cells were restored 
to nearly normal in STZ-induced diabetic treated rats 
after 45  days of therapy. Distorted central vein and 
hepatocytes were reinstated to normal in liver of STZ-
induced diabetic rats treated with various doses of EFx 
when compared to the toxic control. Ascending and 
descending loops were recovered almost to its normal 
morphological features. All histological changes were 
well supported with the restored levels of insulin, glu-
cose, glycosylated hemoglobin. Glucose-6-phosphate 
dehydrogenase (G6PD) is the key enzyme to maintain 
the blood glucose level (Mayes 2000). In streptozo-
tocin-induced diabetic rats, the reduction of G-6-PDH 
activity in liver which obstruct glucose utilisation 
through pentose phosphate pathway as this enzyme 
activity is controlled by insulin (Ugochukwu and 
Babady 2003). The plant extract significantly improves 
this enzyme activity in hepatic tissue which enlighten 
its another possible way of antidiabetogenic activ-
ity. Glucose-6-phosphatase and fructose-1,6-bispho-
phatase play an important role in glucose homeostasis 
Figure 7 Effect of EFx on various antioxidant marker enzymes at the end of therapy, Group 1: normal control; Group 2: STZ (60 mg/kg i.p.); Group 
3: diabetic control + (EFx) (100 mg/kg body weight); Group 4: diabetic control + (EFx) (200 mg/kg body weight) and continue for 45 days; Group5: 
diabetic + diabetic control + (EFx) (300 mg/kg body weight) and continue for 45 days; Group 6: diabetic control + (EFx) (400 mg/kg body weight) 
and continue for 45 days; Group 7: diabetic control + glibenclamide (1 mg/kg body weight) and continue for 45 days.
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(Berg et al. 2001). Insulin deficiency results in the acti-
vation of gluconeogenic enzymes during diabetes. EFx 
administration significantly decreased the activity of 
gluconeogenic enzymes in diabetic rats. The level of 
plasma insulin was found to increase significantly in 
diabetic rats treated with EFx, which might be a pos-
sible reason for significant reduction in the level of 
gluconeogenic enzymes. STZ-induced diabetes is 
characterized by loss in body weight (Al-Shamaony 
et  al. 1994) and this was also observed in the present 
research exertion. The characteristic loss of body 
weight is mainly due to increased muscle wasting in 
diabetes (Swanston-Flatt et  al. 1990). E. ferox salisb. 
seeds extract (EFx) and Glibenclamide administration 
controlled loss of body weight. Hexokinase plays an 
important role in maintaining the blood glucose home-
ostasis (Saxena et  al. 1992). The activity of hepatic 
hexokinase was significantly decreased in the STZ-
induced diabetic rats. Treatment with different doses 
of EFx significantly reversed the activity of hexokinase. 
Increased activity of hexokinase resulted in increased 
glycolysis which inturn causes improvement in glu-
cose utilization and glycolysis for the production of 
energy. Oxidative stress has been linked with obesity 
and insulin resistance, which is recognized by exces-
sive generation of reactive oxygen species (ROS). At 
Figure 8 Effect of Euryale ferox salisb seeds extract (EFx) on histological profile of liver in normal, STZ-induced diabetic untreated and STZ-induced 
diabetic treated wistar rats (original magnification ×40, DXIT 1200, Nikon, Japan). (1) NLIV: heamatoxylin and eosin (H/E) stained sections of liver 
of normal control rats showing normal portal triad along with normal hepatocytes with central vein (yellow arrows). (2) LSTZ: liver section of rats 
received streptozotocin depicting destructed portal trial, disarranged hepatocytes and central vein (red arrows). (3) LEFx100: section of liver sup-
plemented with 100 mg/kg body weight of EFx portraying improvement in structure of portal triad (green arrows). (4) LEFx200: liver section of rats 
received 200 mg/kg body weight of EFx showing arranged hepatocytes (green arrows). (5) LEFx300: section of liver or diabetic rats treated with 
300 mg/kg body weight. of EFx depicting arranged central vein (yellow arrows). (6) LEFx400: liver of diabetic rat showing normal portal traid, central 
vein and hepatocytes (green arrows). (7) LGLIM: liver section of rat administered with Glibenclamide showing normal microvasculature along with 
normal hepatocytes (dark yellow arrows).
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present the indicators for evaluation of ROS are the 
endogenous enzymes such as superoxide dismutase 
(SOD), catalase (CAT), glutathione Peroxidase (GPx) 
and glutathione (GSH). Administration of EFx to STZ-
induced diabetic rats significantly restored the altered 
level of antioxidant enzymes in a dose dependent man-
ner. Glycosylation of proteins, oxidative stress and 
chronic hyperglycemia potentiate the increased risk of 
cardiovascular diseases through the altered lipid pro-
file. As diabetes is a metabolic disorder, it is character-
ized not only by increased glucose concentrations but 
also by altered level of lipid profile. An altered lipid 
profile was observed with significantly increased con-
centration of TC, TGs, LDL and HDL and decreased 
concentration of HDL among diabetic rats (DC) than 
their normal counterparts. Administration of EFx for 
45  days significantly improvised the altered level of 
TC, TGs. LDL and HDL in a dose dependent man-
ner. Therefore, the plausible mechanism of action of 
EFx in controlling the blood glucose level might be the 
enhancement of secretion of insulin from pancreatic 
β-cells. Furthermore, the mechanism of correction of 
lipid profile might be due the improved glycogenesis in 
the liver.
Figure 9 Effect of Euryale ferox salisb seeds extract (EFx) on histological profile of pancreas in normal, STZ-induced diabetic untreated and STZ-
induced diabetic treated wistar rats (original magnification ×10, DXIT 1200, Nikon, Japan). (1) NPAN: heamatoxylin and eosin (H/E) stained sections 
of pancreas of normal control rat portraying normal islet of langerhans shown by yellow arrows. (2) PSTZ: pancreatic section of streptozotocin 
induced diabetic rat showing no/destroyed islet of langerhans and beta cells depicted by red arrows. (3) PEFx-100: pancreatic section of STZ-
induced diabetic rats treated with EFx at 100 mg/kg body weight showing small number of islet of langerhans (green arrows). (4) PEFx-200: section 
of pancreas of STZ-induced diabetic rats treated with EFx at 200 mg/kg body weight portraying increased number of islet of langerhans with small 
proportions of beta cells (green arrows). (5) PEFx-300: pancreas of diabetic rats treated with 300 mg/kg body weight. EFx depicting nearly normal 
islet of langerhans (green arrows). (6) PEFx-400: sections of pancreas of diabetic treated rats with 400 mg/kg body weight. EFx showing normal islet 
of langerhans with numerous beta cells (green arrows). (7) PGLIM: pancreatic section of diabetic rats treated with Glibenclamide showing normal 
pancreatic islet of langerhans with enhancement in the number of beta cells (dark yellow arrow).
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Conclusion
The above results indicated that E. Ferox salisb. seeds 
extract protect β-cells against ROS-mediated destruc-
tion by improvising the levels of antioxidant enzymes 
and minimizing hyperglycemia which could be due to 
release of insulin from remnant and recovered β-cells in 
pancreas in STZ-induced diabetic rats as confirmed by 
the ultrastructural, histopathological studies. The above 
research exertion clearly indicates that ethanolic extract 
of E. Ferox salisb. may be utilized as important source of 
natural antioxidants with antidiabetic and antihyperlipi-
demic potential and can be used as plausible food addi-
tives or as a functional food in future.
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